OncoCyte Corporation (OCX)
Automate Your Wheel Strategy on OCX
With Tiblio's Option Bot, you can configure your own wheel strategy including OCX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol OCX
- Rev/Share 0.1496
- Book/Share 0.3977
- PB 8.0467
- Debt/Equity 0.3404
- CurrentRatio 3.745
- ROIC -1.1247
- MktCap 91517760.0
- FreeCF/Share -0.8925
- PFCF -3.991
- PE -1.4126
- Debt/Assets 0.0576
- DivYield 0
- ROE -7.6691
- Rating
- Score
- Recommendation
- P/E Score
- DCF Score
- P/B Score
- D/E Score
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | OCX | Lake Street | -- | Buy | -- | $5 | March 28, 2025 |
News
Best Momentum Stocks to Buy for May 6th
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Positive
MAIA, BYRN and OCX made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on May 6, 2025.
Read More
New Strong Buy Stocks for May 6th
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Positive
MAIA, BYRN, OCX, BBVA and HMY have been added to the Zacks Rank #1 (Strong Buy) List on May 6, 2025.
Read More
Oncocyte Provides Positive Update on Clinical Trial Progress
Published: April 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
IRVINE, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp., (Nasdaq: OCX), a leading diagnostics technology company, today provided a positive update on its substantial progress toward initiating its clinical trial, which is a major step required to obtain regulatory authorization to deliver an organ transplant rejection monitoring test kit to the market.
Read More
Oncocyte's Proprietary Assay Demonstrates Long-Term Clinical Validity
Published: April 29, 2025 by: GlobeNewsWire
Sentiment: Neutral
Robust data set of 131 patients with 151 kidney biopsies enrolled over four years at Charité University in Berlin Supports market expansion for testing of high-risk patient population New findings advance understanding of the biology of organ rejection IRVINE, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp., (Nasdaq: OCX), a leading diagnostics technology company, today announced the publication of new and positive data regarding its proprietary blood-based transplant rejection assay.
Read More
OncoCyte (OCX) Upgraded to Buy: What Does It Mean for the Stock?
Published: April 07, 2025 by: Zacks Investment Research
Sentiment: Positive
OncoCyte (OCX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
About OncoCyte Corporation (OCX)
- IPO Date 2015-12-30
- Website https://oncocyte.com
- Industry Biotechnology
- CEO Joshua Riggs
- Employees 46